Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

15.08.2022 - Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and ...

Related Keywords

New York ,United States ,Australia ,Japan ,United Kingdom ,Sydney ,New South Wales ,Massachusetts ,Vancouver ,British Columbia ,Canada ,Boston ,American ,British ,Johnk Scott Jr ,Michael Rosol ,Navidea Manocept ,Muzib Abdul Razak ,Steven Grinspoon ,Small Business Innovation Research ,Navidea Biopharmaceuticals Inc ,National Institutes Of Health ,Harvard Medical School ,Professor Of Medicine At Harvard Medical School ,Department Of Surgical Oncology ,University Of Sydney ,Exchange Commission ,Maxim Group ,Company Vice ,Cardinal Health ,Securities Exchange ,Crown Princess Mary Cancer Centre ,Society Of Nuclear Medicine ,Attention Syndicate Department ,Tilmanocept Imaging ,Yearly Prediction ,Severe Active Rheumatoid Arthritis ,Imaging Agents Binding ,Selective Blocking ,Off Target Liver ,Nuclear Medicine ,Imaging Annual Meeting ,Tumor Myeloid Directed Therapies Summit ,Non Calcified Plaque ,Specific Immune Activation Pathways ,Targeted Molecular Imaging Approach ,Massachusetts General Hospital ,Infectious Diseases ,Principal Investigator Steven Grinspoon ,Metabolism Unit ,Harvard Medical ,Surgical Oncology ,Neck Surgery ,Vice Chair ,Chief Medical Officer ,National Institutes ,Securities Act ,Securities Exchange Act ,Annual Report ,Navidea Biopharmaceuticals Stock ,Navidea Biopharmaceuticals ,